In exchange for rights to jointly co-develop and co- market the products, Shionogi will pay a one time fee and share costs to Shire.
Shire ADHD business senior vice president Mike Yasick said this agreement with Shionogi underscores their commitment to help patients diagnosed with ADHD.
"We look forward to work with the Shionogi team on efforts to enhance awareness in Japan about the impact undiagnosed and untreated ADHD can have on our societies, and the value that new treatment options can deliver for ADHD patients," Yasick said.